Agenda trial concluded this month and we are awaiting THE most important results, OS data.
Good results and market cap will quickly adjust to the tremendous value Genasense will bring. Along with NDA and FDA fast track approval. The PPS will adjust literally overnight and note holders will have there debt called upon for the fixed return shortly after. If OS results are significant theirs no doubt FDA will approve Genasense this time around.
On the flip side, statistically insignificant results will bring about the next R/S and massive noteholder conversions. Genta will probably do another round of toxic financing to push Tesetaxel to phase III. Anybody holding shares after the bad new will loose 80-90% literally overnight.
After insignificant PFS, why waste tens of millions of dollars to continue the Agenda Trial? Why not put Geasense in the grave right away and focus all resources on Tesetaxel? The reason is researchers have seen something significant that Genasense has to offer, even in the trial prior to the first NDA, Genasense hit it's primary endpoint. Genta has learned a lot from the past trials and are very confident Genasense will show positive OS results in patients with a low to normal LDH.
Peasodos
AI
